Low-density lipoprotein cholesterol levels and statin treatment by HIV status among multicenter AIDS cohort study men

AIDS Research and Human Retroviruses

Volumn 31, Issue 6, 2015, Pages 593-602

  Monroe, Anne K ^a   Fu, Wei ^b   Zikusoka, Michelle N ^a   Jacobson, Lisa P ^b   Witt, Mallory D ^c   Palella, Frank J ^d   Kingsley, Lawrence A ^e   Post, Wendy S ^a,b   Brown, Todd T ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; TRIACYLGLYCEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE;

ADULT; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; HEALTH INSURANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEN WHO HAVE SEX WITH MEN; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; DYSLIPIDEMIAS; HIV INFECTIONS; MIDDLE AGED; MULTICENTER STUDY;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COHORT STUDIES; DYSLIPIDEMIAS; HIV INFECTIONS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MALE; MIDDLE AGED;

EID: 84930250829     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2014.0126     Document Type: Conference Paper

References (50)

1. Palella FJ Jr, Baker RK, Moorman AC, et al.: Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006;43(1):27-34.
2. Sterne JAC, Hernán MA, Ledergerber B, et al.: Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: A prospective cohort study. Lancet 2005; 366 (9483):378-384.
3. Barbaro G: Highly active antiretroviral therapy-associated metabolic syndrome: Pathogenesis and cardiovascular risk. Am J Ther 2006;13(3):248-260.
4. Wada N, Jacobson LP, Cohen M, et al.: Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013; 177(2):116-125.
5. Saves M, Chêne G, Ducimetiere P, et al.: Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37:292-298.
6. Triant V, Lee H, Hadigan C, and Grinspoon S: Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007;92(7):2506-2512.
7. Currier J, Taylor A, Boyd F, et al.: Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003;33(4):506-512.
8. Freiberg MS, Chang CCH, Skanderson M, et al.: The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C. Circulation 2011;4(4):425-432.
9. Palella FJ Jr, Baker RK, Buchacz K, et al.: Increased mortality among publicly insured participants in the HIV Outpatient Study despite HAART treatment. AIDS 2011; 25(15):1865-1876.
10. Sackoff JE, Hanna DB, Pfeiffer MR, and Torian LV: Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006;145(6):397-406.
11. Brown TT, Cole SR, Li X, et al.: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165(10):1179-1184.
12. De Wit S, Sabin CA, Weber R, et al.: Incidence and risk factors for new-onset diabetes in HIV-infected patients. Diabetes Care 2008;31(6):1224-1229.
13. Baekken M, Os I, Sandvik L, and Oektedalen O: Hypertension in an urban HIV-positive population compared with the general population: Influence of combination antiretroviral therapy. J Hypertens 2008;26(11):2126-2133.
14. Satlin MJ, Hoover DR, and Glesby MJ: Glycemic control in HIV-infected patients with diabetes mellitus and rates of meeting American Diabetes Association management guidelines. AIDS Patient Care STDS 2011;25(1):5-12.
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-3421.
16. Grundy SM, Cleeman JI, Merz CNB, et al.: Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol 2004;44(3):720-732.
17. Anderson KM, Wilson P, Odell PM, and Kannel WB: An updated coronary risk profile. A statement for health professionals. Circulation 1991;83(1):356-362.
18. Baigent C, Keech A, Kearney Pa, et al.: Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective metaanalysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-1278.
19. Zafrir B and Cohen S: Primary prevention in high-risk dyslipidemic patients without an established cardiovascular disease: Undertreatment and rationale for lipid-lowering therapy. Eur J Int Med 2006;17(7):495-499.
20. Pearson TA: The undertreatment of LDL-cholesterol: Addressing the challenge. Int J Cardiol 2000;74:S23-S28.
21. Stone NJ, Robinson J, Lichtenstein AH, et al.: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25 Pt B):2889-2934.
22. Jellinger PS, Smith DA, Mehta AE, et al.: American association of clinical endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocrine Practice 2012;18:1-78.
23. American Association of Clinical Endocrinologists (AACE): Press statement. http://media.aace.com/press-release/pressstatement. Accessed March 27, 2014.
24. Reinsch N, Neuhaus K, Esser S, et al.: Are HIV patients undertreated? Cardiovascular risk factors in HIV:R of the HIV-HEART study. Eur J Prev Card 2012;19(2):267-274.
25. Nüesch R, Wang Q, Elzi L, et al.: Risk of cardiovascular events and blood pressure control in hypertensive HIVinfected patients: Swiss HIV Cohort Study (SHCS). JAIDS J Acquir Immune Defic Syndr 2013;62(4):396-404.
26. Kaslow RA, Ostrow DG, Detels R, et al.: The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987;126(2):310-318.
27. Friedewald WT, Levy RI, and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18(6):499-502.
28. Allain CC, Poon LS, ChanCS, et al.: Enzymatic determination of total serum cholesterol. Clin Chem 1974;20(4):470-475.
29. Warnick GR and Albers J: A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating high density lipoprotein cholesterol. J Lipid Res 1978;19(1):65-76.
30. Bucolo G, Yabut J, and Chang TY: Mechanized enzymatic determination of triglycerides in serum. Clin Chem 1975; 21(3):420-424.
31. Schouten J, Wit FW, Stolte IG, et al.: Comorbidity and ageing in HIV-1 infection: The AGEhIV Cohort Study. XIX International AIDS Conference. July 22-27, 2012. Washington, DC. Abstract THAB0205.
32. Lichtenstein KA, Armon C, Buchacz K, et al.: Provider compliance with guidelines for management of cardiovascular risk in HIV-infected patients. Prev Chron Dis 2013;10:E10.
33. Casagrande SS, Fradkin JE, Saydah SH, et al.: The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013;36(8):2271-2279.
34. Banta MR, Ma F, Bravata DM, et al.: Incidence of and factors associated with achieving target lipid levels in patients with peripheral arterial disease. J Gen Intern Med 2006;21(7):711-714.
35. Riddler S, Li X, Chu H, et al.: Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 20078(5):280-287.
36. Subramanian S, Tawakol A, Burdo TH, et al.: Arterial inflammation in patients with HIV. JAMA 2012;308(4):379-386.
37. Zanni MV, Abbara S, Lo J, et al.: Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS 2013;27(8):1263-1272.
38. Cramer JA, Scheyer RD, and Mattson RH: Compliance declines between clinic visits. Arch Intern Med 1990;150(7): 1509-1510.
39. Downs JR, ClearfieldM,Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA 1998;279(20):1615-1622.
40. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360(9326):7-22.
41. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). The Lancet 1994;344(8934):1383-1389.
42. United States Food and Drug Administration: FDA Drug Safety Communication: Important safety label changes to cholesterol-lowering statin drugs. www.fda.gov/Drugs/DrugSafety/ucm293101.htm. Accessed March 27, 2014.
43. Atorvastatin prescribing information: http://labeling.pfizer.com/ShowLabeling.aspx?id = 587. Accessed March 27, 2014.
44. Rosuvastatin prescribing information: http://1.astrazenecaus. com/pi/crestor.pdf. Accessed March 27, 2014.
45. Gibson K and Rindone JP: Experience with statin use in patients with chronic hepatitis C infection. Am J Cardiol 2005;96(9):1278-1279.
46. Khorashadi S, Hasson NK, and Cheung RC: Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol 2006;4(7):902-907.
47. Chalasani N, Aljadhey H, Kesterson J, et al.: Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. Gastroenterology 2004;126(5):1287-1292.
48. Stroup JS and Harris B: Is statin therapy safe in patients with HIV/hepatitis C coinfection? Proc (Bayl Univ Med Cent) 2010;23(2):111-113.
49. Milazzo L, Menzaghi B, Corvasce S, et al.: Safety of statin therapy in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2007;46(2):258-260.
50. Athyros VG, Tziomalos K, Gossios TD, et al.: Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis. Lancet 2010;376(9756):1916-1922.